Apogee Q4 2024 Earnings Report
Key Takeaways
Apogee Therapeutics reported full year 2024 financial results, highlighting the accelerated execution of the Phase 2 APEX clinical trial for APG777 and the positive interim Phase 1 results for APG990. The company's cash, cash equivalents, and marketable securities totaled $731.1 million, providing a runway into Q1 2028.
Phase 2 APEX clinical trial for APG777 is progressing faster than expected.
APG279 Phase 1b head-to-head study vs. DUPIXENT is supported by positive APG990 interim Phase 1 results.
APG990 demonstrated potential for three- and six-month dosing in combination with APG777.
Cash, cash equivalents and marketable securities totaled $731.1 million, providing runway into Q1 2028.
Apogee
Apogee
Forward Guidance
Apogee Therapeutics is looking forward to an exciting and productive 2025 with several meaningful catalysts expected.